Retinitis Pigmentosa

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2026-02-16
EMA Authorised: Luxturna (voretigene neparvovec) — Novartis Europharm Limited
The European Medicines Agency authorised Luxturna (voretigene neparvovec) from Novartis Europharm Limited for the treatment of inherited ret…